Clinical Trial Search

Primary: Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR), as Assessed by the Independent Review Committee…

Primary: Percentage of Participants Reporting Pain Freedom at 2 Hours Post-dose (First Migraine Attack) — 21.9; 25.1; 10.2 Percentage of participants — p=<0.001

Primary: Total Harris Hip Score — 95.6; 94.9 units on a scale — p=<0.001

Primary: Changes of Macular Pigment Optical Density (MPOD) During 48 Weeks and 2 Years — 0.315; 0.307; 0.315; 0.320 density units — p=<0.05

Primary: Cocaine Use (Measured by Timeline Follow Back and Urine Screen From Week 2-week 14) — 9.3; 7.2; 10.1; 10.5 number of cocaine negative urine samples

Primary: Change From Baseline in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Score — 0.0; -3.7; -3.4; -3.9 score on a scale…

Primary: Mean Apnea-Hypopnea Index (AHI) — 17.07; 14.41 Events per hour

Primary: Trocar Slippages With LaproStop — 1; 2; 3 Participants

Primary: Change in Weight — -1.4; -2.8; -1.4 Kilograms — p=<0.05

Primary: Failure of Drug to Control Systolic Blood Pressure (SBP) < 140 mmHg — 1; 11 participants

Primary: Number of Negative Breath Alcohol and Urine Drug Screens Out of Possible 16 — 11.93; 10.39 negative alcohol and drug screens — p=<.001

Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-∞) After Single Dose Suvorexant: Moderate Hepatic Insufficiency Participants…

Primary: Percentage of Participants Who Experienced Cataplexy Adverse Events (AEs) During the Double-Blind (DB) Treatment Phase — 0.0; 0.0 percentage of participants

Primary: Eye Contact/Gaze During 10 Minute Social Challenge Task — 15.4; 20.9; 17.0 eye contact/gaze events per 10 minutes

Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26